Product Description
Mechanisms of Action: Plasmin Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous,Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Bangladesh | Brazil | Canada | China | Dominican Republic | Ecuador | Greece | Hong Kong | Hungary | India | Ireland | Italy | Korea | New Zealand | Portugal | Russia | Taiwan | Ukraine | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|